Skull-based cancers are complex and heterogeneous diseases that require complex multidisciplinary management between head and neck surgeons, medical oncologists and radiation oncologists. Emerging data has given novel insights into the optimal treatment of sinonasal and skull-based malignancies.

This educational activity will focus on the identification and management of oral and swallowing complications caused by cancer-directed therapy for patients with head and neck cancer.

This session explores some of the basic radiobiologic principles of radiopharmaceutical therapy.

As the interest and use of Radiopharmaceutical Therapy is rapidly growing, so too is the practice of dosimetry. However, the methods and applications vary widely from site to site and often from practitioner to practitioner.

Technological advances have progressed rapidly, expanding the tools used for monitoring and treatment of patients with head/neck cancer. As these technologies approach clinical deployment it is essential to understand their potential applications.

This session reviews head and neck cancers from a patient perspective.

The gaps in practice include the proper integration of new data with existing trials and practices in viral-driven head and neck cancers.

This session reviews head and neck cancers from a patient perspective.

In this session, expert speakers will discuss the future of theranostics. The speakers pay specific attention to the following topics: novel cancer-specific targets, novel pan-cancer targets, and the potential use of alpha emitters.

Long-term treatment related toxicities are a growing issue in the longitudinal care of head and neck cancer patients as our treatments have improved survival.